Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cleveland BioLabs has entered into a strategic research partnership with Roswell Park Cancer Institute to develop its cancer and radio-protectant drug candidates.
Subscribe to our email newsletter
Roswell Park believes the partnership could grant cancer patients early access to promising new treatments and provide a commercial development pathway for new discoveries.
Roswell Park and various New York agencies will provide Cleveland BioLabs with up to $5 million of non-dilutive funding. Cleveland BioLabs will establish a major research and clinical facility at the Roswell Park campus in Buffalo, New York. The company will also have an open-ended license to any basic research conducted within or in collaboration with its Roswell Park laboratory.
“They are offering a unique treatment platform and an extensive pipeline of cancer drug candidates in advanced development, including their phase II oral, cancer compound and family of radio-protectants. The company’s recent finding regarding proliferation of adult stem cells following administration of one of its radio-protectant compounds is particularly interesting,” stated Dr David Hohn, president & CEO of Roswell Park Cancer Institute.
Roswell Park hopes the partnership will grant cancer patients early access to promising new treatments and provide a commercial development pathway for new discoveries.